Proactive Investors - Run By Investors For Investors

Cellmid raises $9 million for distribution and invites shareholders to invest $1 million

The company will use the capital raised as fuel for distributing its products in Australian and international markets.
Australian dollar notes
There was strong demand from new and existing institutional investors

Cellmid Limited (ASX:CDY) has raised $9 million from sophisticated and institutional investors and will invite shareholders to participate in a $1 million share placement plan.

The $9 million from high-quality investors is split into two tranches, with one to be approved by shareholders.



Cellmid said the placement “closed with strong demand from new and existing institutional investors”.

READ: Cellmid lays out major plan for product and distribution expansion

Proceeds will provide working capital to drive distribution of Cellmid’s products and grow its health business, pushing out its flagship évolis product range, and facilitating distribution in Australia, New Zealand and new global markets.

Sydney-based Cellmid hopes to increase its proceeds from an exclusive distribution agreement with Fillerina for the two Southern Hemisphere countries.

READ: Cellmid's year-to-date sales exceed full-year sales for 2017 with further momentum expected

Cellmid chairman Dr David King said: “We are delighted to secure funding for the expansion of our consumer health business at this critical stage.

“The funding will allow us to turbo charge our growth plans and take the company closer to profitability.”

It comes at a fortuitous time as distribution channels have been set up in major global markets such as China and the US.

READ: Cellmid set to launch its évolis hair care products in the lucrative Chinese market

The Blue Ocean Equities Pty Ltd-led 23.7 million placement was priced at 38 cents a share, which was a 17.8% discount to Cellmid’s 30-day VWAP on its last trading day of July 26.

The tranche that investors will be asked to approve at an annual meeting pencilled in for September 7 will be a 12.5% placement to directors: 11.1% to the Dennis Eck family, 0.3% to Martin Cross and 1.1% to managing director and CEO Maria Halasz.

That tranche makes up more than 19 million shares and about $7.3 million of the capital raising while the remaining unconditional placement will bring in about $1.7 million.

The unconditionally approved shares will be settled on Friday and allotted next Monday.

If the director component of the share-raising is approved, the shares are expected to be settled on August 11 and allotted the next day.

READ: Cellmid secures partnership with Bloomingdales to sell évolis

Shareholders will be able to participate in the offer at the same buy-in price for a $15,000 maximum increase to their investment.

The investors must have been on the share register at 7pm Australian Eastern Standard Time yesterday and be registered to an Australian or New Zealand address.

View full CDY profile View Profile

Cellmid Ltd Timeline

Related Articles

May 09 2019
Here we take a look under the hood of Shield Therapeutics
scientist in a lab
April 12 2019
Danish giant Novo Nordisk recently signed up to use its NDD platform, and bosses expect more collaboration deals in the coming months
man with erectile dysfunction
June 17 2019
Headline results from the trial of MED2005 are due before the end of 2019, while Futura is also confident of hearing back from UK regulators about its pain relief gel later in the year

© Proactive Investors 2019

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use